New Zealand markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
41.27+1.26 (+3.15%)
At close: 04:00PM EDT
41.23 -0.04 (-0.10%)
After hours: 04:35PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 17.27B
Enterprise value 21.46B
Trailing P/E 27.64
Forward P/E 12.14
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.39
Price/book (mrq)2.98
Enterprise value/revenue 9.42
Enterprise value/EBITDA 15.23

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-0.27%
S&P500 52-week change 3-3.48%
52-week high 347.10
52-week low 334.86
50-day moving average 340.66
200-day moving average 339.33

Share statistics

Avg vol (3-month) 32.12M
Avg vol (10-day) 32.01M
Shares outstanding 5435.32M
Implied shares outstanding 6N/A
Float 8340.67M
% held by insiders 115.48%
% held by institutions 163.11%
Shares short (12 May 2022) 48.35M
Short ratio (12 May 2022) 43.05
Short % of float (12 May 2022) 42.69%
Short % of shares outstanding (12 May 2022) 41.92%
Shares short (prior month 13 Apr 2022) 48.19M

Dividends & splits

Forward annual dividend rate 40.76
Forward annual dividend yield 41.90%
Trailing annual dividend rate 30.70
Trailing annual dividend yield 31.75%
5-year average dividend yield 4N/A
Payout ratio 448.95%
Dividend date 314 Jun 2022
Ex-dividend date 418 May 2022
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 26.44%
Operating margin (ttm)62.37%

Management effectiveness

Return on assets (ttm)5.34%
Return on equity (ttm)12.12%

Income statement

Revenue (ttm)2.28B
Revenue per share (ttm)5.35
Quarterly revenue growth (yoy)-1.90%
Gross profit (ttm)1.84B
Net income avi to common (ttm)602.37M
Diluted EPS (ttm)1.37
Quarterly earnings growth (yoy)-25.10%

Balance sheet

Total cash (mrq)2.34B
Total cash per share (mrq)5.38
Total debt (mrq)7.1B
Total debt/equity (mrq)70.02
Current ratio (mrq)21.95
Book value per share (mrq)13.27

Cash flow statement

Operating cash flow (ttm)1.95B
Levered free cash flow (ttm)-1.06B